ecancermedicalscience

Case Report

Cryptococcal meningoencephalitis in patients with mantle cell lymphoma on ibrutinib

17 May 2018
Kai Sun, Saro Kasparian, Swaminathan Iyer, Sai Ravi Pingali

Ibrutinib, a Bruton’s tyrosine kinase inhibitor, has been increasingly widely used in relapsed and refractory mantle cell lymphoma (MCL) and chronic lymphocytic leukaemia [1, 2]. With its use becoming more common, there have been emerging case reports of opportunistic infections like cryptococcal infections [3–8]. These infections in patients receiving ibrutinib were mostly reported in patients with chronic lymphocytic leukaemia, who have poor immune reconstitution. Here, we report two cases of cryptococcal meningoencephalitis in patients with MCL on ibrutinib.

Related Articles

Tooba Ali, Laraib Khan, Bilal Mazhar Qureshi, Asim Hafiz, Maria Tariq, Khurram Minhas, Nasir Ali, Ahmed Nadeem Abbasi
Hani Shihadeh, Ahmad Yousef, Ahmad Al-Leimon, Hussein Abu-Rumman, Laith Kreshan
Dandara Menezes de Araujo Oliveira, Rossana Veronica Mendonza Lopez, Lady Paola Aristizabal Arboleda, Maria Paula Curado
Bennani Mechita Nada, Messaoud Sara, Elboukhari Elmamoun Yousra, Amina Kili, El Khorassani Mohammed, Lakhrissi Mariam, Isfaoun Zineb, El Ansari Naoual, Razine Rachid, Obtel Majdouline, El Kababri Maria, Hessissen Laila